CLPBY (Coloplast AS) Cyclically Adjusted Revenue per Share: $1.70 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLPBY Coloplast AS CLPBY
77 GF Score
Price $6.70
GF Value $13.05
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is Coloplast AS Cyclically Adjusted Revenue per Share?

Coloplast AS CLPBY -1.47% 77 Cyclically Adjusted Revenue per Share is $1.70 as of Mar. 2026. GuruFocus rates CLPBY with a GF Score™ of 77/100 and a GF Value™ of $13.05 (Significantly Undervalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Coloplast AS's adjusted revenue per share for the three months ended in Mar. 2026 was $0.487. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $1.70 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Coloplast AS's average Cyclically Adjusted Revenue Growth Rate was 5.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 6.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 9.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Coloplast AS was 10.30% per year. The lowest was 5.60% per year. And the median was 8.45% per year.

As of today (2026-08-04), Coloplast AS's current stock price is $6.70. Coloplast AS's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $1.70. Coloplast AS's Cyclically Adjusted PS Ratio of today is 3.94.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Coloplast AS was 16.78. The lowest was 3.52. And the median was 9.80.


Coloplast AS  (OTCPK:CLPBY) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Coloplast AS's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=6.70/1.70
=3.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Coloplast AS was 16.78. The lowest was 3.52. And the median was 9.80.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Coloplast AS Cyclically Adjusted Revenue per Share Related Terms


Coloplast AS Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Coloplast AS's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coloplast AS Cyclically Adjusted Revenue per Share Chart

Coloplast AS Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.15 1.14 1.31 1.48 1.66

Coloplast AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.48 1.63 1.66 1.65 1.70

CLPBY vs ISRG, BDX, MDLN: Cyclically Adjusted Revenue per Share Comparison

For the Medical Instruments & Supplies subindustry, Coloplast AS's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coloplast AS Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Coloplast AS's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Coloplast AS's Cyclically Adjusted PS Ratio falls into.


CLPBY
77GF Score
Coloplast AS CLPBY
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Coloplast AS Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Coloplast AS's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.487/121.6800*121.6800
=0.487

Current CPI (Mar. 2026) = 121.6800.

Coloplast AS Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.262 100.600 0.317
201609 0.266 100.200 0.323
201612 0.251 100.300 0.305
201703 0.263 101.200 0.316
201706 0.278 101.200 0.334
201709 0.299 101.800 0.357
201712 0.296 101.300 0.356
201803 0.315 101.700 0.377
201806 0.312 102.300 0.371
201809 0.312 102.400 0.371
201812 0.310 102.100 0.369
201903 0.312 102.900 0.369
201906 0.327 102.900 0.387
201909 0.319 102.900 0.377
201912 0.329 102.900 0.389
202003 0.335 103.300 0.395
202006 0.313 103.200 0.369
202009 0.341 103.500 0.401
202012 0.364 103.400 0.428
202103 0.357 104.300 0.416
202106 0.367 105.000 0.425
202109 0.378 105.800 0.435
202112 0.368 106.600 0.420
202203 0.382 109.900 0.423
202206 0.391 113.600 0.419
202209 0.380 116.400 0.397
202212 0.409 115.900 0.429
202303 0.410 117.300 0.425
202306 0.418 116.400 0.437
202309 0.397 117.400 0.411
202312 0.431 116.700 0.449
202403 0.427 118.400 0.439
202406 0.442 118.500 0.454
202409 0.460 118.900 0.471
202412 0.438 118.900 0.448
202503 0.446 120.200 0.451
202506 0.477 120.700 0.481
202509 0.486 121.600 0.486
202512 0.491 121.200 0.493
202603 0.487 121.680 0.487

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $1.70 mean?
Coloplast AS (CLPBY) has a Cyclically Adjusted Revenue per Share of $1.70 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Coloplast AS and its competitors.
Is Coloplast AS's Cyclically Adjusted Revenue per Share too high?
Coloplast AS's current Cyclically Adjusted Revenue per Share is $1.70. Overall, Coloplast AS has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's Cyclically Adjusted Revenue per Share compare to ISRG and BDX?
Coloplast AS's Cyclically Adjusted Revenue per Share of $1.70 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Coloplast AS and its competitors. Coloplast AS's current Cyclically Adjusted Revenue per Share is $1.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBY) is currently considered Significantly Undervalued. The stock's GF Value™ is $13.05, compared to a current price of $6.70 — trading 48.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $1.70. Coloplast AS's overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Coloplast AS (CLPBY), the current Cyclically Adjusted Revenue per Share is $1.70 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Coloplast AS (CLPBY) Overvalued in 2026?

Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued. The current stock price of $6.70 is trading 48.7% below its estimated GF Value™ of $13.05. GuruFocus considers Coloplast AS to be Significantly Undervalued.

Key valuation signals for CLPBY:

  • Cyclically Adjusted Revenue per Share: $1.70
  • GF Value™: $13.05 vs. price of $6.70 (48.7% below fair value)
  • GF Score™: 77/100 with 6 warning signs

No single metric tells the full story. See the CLPBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Coloplast AS Business Description

Address Holtedam 1-3, Humlebaek, DNK, DK-3050
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
77GF Score

Get the complete analysis for CLPBY

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.70
Price
$13.05
GF Value